Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trenibotulinumtoxinE
- Development stage
- Phase 3
- Lead developer
- AbbVie
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
TrenibotulinumtoxinE (TrenibotE) is a first-in-class botulinum neurotoxin serotype E developed for the treatment of moderate to severe glabellar lines (frown lines between the eyebrows). Unlike traditional botulinum toxin type A products (such as onabotulinumtoxinA/BOTOX), TrenibotE is characterized by a rapid onset of action—clinical effects can be observed as early as 8 hours after administration—and a shorter duration of effect lasting approximately 2–3 weeks. This profile may address concerns among new patients about unnatural or prolonged results from aesthetic neurotoxins. The drug acts primarily by inhibiting acetylcholine release at neuromuscular junctions through SNARE protein antagonism and also exhibits glutamate antagonism and neuromuscular blocking activity. Developed originally by Bonti and further advanced by AbbVie/Allergan Aesthetics, TrenibotE has completed pivotal Phase 3 trials with positive results for efficacy and safety in over 2,100 patients[1][4][5][7][8].
- Brand names
- TrenibotE
- Other names
- botulinum toxin E
02
Targets
SNAP25 (Synaptosome-associated protein 25)VAMP (SNARE Protein Complex)
Beyond the preview
Go deeper on trenibotulinumtoxinE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trenibotulinumtoxinE.